Table 5.

Results of multiple regression analyses.

a. VAS at 12 Months Post-injection (VAS Post 12 M)
n.s.
b. Change in VAS at 12 months Post-injection (Change in VAS)
n.s.
c. Percent Change in VAS at 12 months Post-injection (% change in VAS)
	β	βstand	T	p value
Number of targeted discs	−40.7	−0.57	−2.3	<0.05
R2: 0.32, p < 0.05
d. ODI at 12 months Post-injection (ODI Post 12 M)
	β	βstand	T	p value
Posterior HIZ	17.6	0.55	2.2	0.05
R2: 0.31, p = 0.05
e. Change in ODI at 12 months Post-injection (Change in ODI)
n.s.
f. Percent Vhange in ODI at 12 Months Post-injection (% Change in ODI)
	β	βstand	T	p value
Posterior HIZ	−49.4	−0.57	−2.9	<0.05
Number of targeted discs	−43	−0.54	−2.7	<0.05
R2: 0.60, p = 0.010.
g. RDQ at 12 Months Post-injection (RDQ Post 12 M)
	β	βstand	T	p value
Treatment group	−5.7	−0.59	−2.4	<0.05
R2: 0.35, p < 0.05
h. Change in RDQ at 12 Months Post-injection (Change in RDQ)
n.s.
i. Percent Change in RDQ at 12 months Post-injection (% Change in RDQ)
	β	βstand	T	p value
Treatment group	43.2	0.62	2.6	<0.05
R2: 0.38, p < 0.05

VAS: visual analogue scale; ODI: Oswestry Disability Index [32]; RDQ: Roland–Morris Disability Questionnaire [33].